Prisijunk prie mūsų



Užsisakyti naujienlaiškį

Vardas:
El. paštas:

Naujiena
Dėl 2% nuo gyventojų pajamų mokesčio skyrimo Spausdinti

Mielieji, jei dar neturite numatę, kam skirsite savuosius 2% nuo gyventojų pajamų mokesčio, nuoširdžiai prašome paremti VŠĮ "Kartu lengviau".  Nuo sausio 1 d. iki gegužės 1 d. prašymą Forma FR0512 gyventojas turi pateikti apskrities valstybinei mokesčių inspekcijai, arba adresu Didlaukio 51a-34, Vilnius, LT30803.

Mūsų organizacijos veikla skirta pagalbos teikimui sergantiems galvos smegenų augliais ir jų artimiesiems.
Viešoji įstaiga "Kartu lengviau“
Įmonės kodas: 302065537
Adresas: Didlaukio 51a-34, Vilnius
 
Sveikiname Šv. Velykų proga! Spausdinti

 

Sveikiname Jus Šv. Velykų proga!

Tegul kartu su pavasariu į Jūsų namus ateis ramybė, šiluma, džiaugsmas ir tikėjimas.

 

Kartu lengviau

 

 

 
IBTA 2012 m. kovo mėn. naujienos (anglų k.) Spausdinti

Scandinavian countries: IBTA representatives will speak at the Norwegian brain tumour group's annual meeting at Sandefjord during 21-22 April and will attend the meeting of the Danish group in Copenhagen on 24 April.

Visual field testing: An Edinburgh (UK) based company i2eye Diagnostics has developed  a device called  SVOP (saccadic vector optokinetic perimetry) to measure a person's central and peripheral vision by instinctive responses to light and movement and if any issues are identified they can be explored for the possibility of stroke or a brain tumour.

Nanoparticle radiation: Researchers in the US are preparing a clinical trial to test the effectiveness of a new method they have developed of encapsulating the short half-life rhenium-186 in fat molecules which are infused into a brain tumour.

Conference in Poland: The early bird registration deadline for the "Brain Tumors 2012" scientific conference to be held in Warsaw, Poland, during 28-20 May is 15 April.

The cellphone discussion: In a News Note published on 8 March the US National Cancer Institute reported: "In a new examination of United States cancer incidence data, investigators at the National Cancer Institute (NCI) reported that incidence trends have remained roughly constant for glioma, the main type of brain cancer hypothesized to be related to cell phone use. The researchers found that while cell phone use increased substantially over the period 1992 to 2008 (from nearly zero to almost 100 percent of the population), the U.S. trends in glioma incidence did not mirror that increase. Results of this study were published online March 8, 2012, in the British Medical Journal."

 

Visas Tarptautinės sergančiųjų galvos smegenų augliais asociacijos 2012 m. kovo mėn. naujienas anglų kalba rasite čia.

 

Šaltinis: www.theibta.org

 
IBTA 2012 m. vasario mėn. naujienos (anglų k.) Spausdinti

Avastin: The appearance of a counterfeit version of the injectable drug bevacizumab (Avastin) in the USA has been extensively reported in the media. The drug is used in the treatment of brain tumours, among other cancers. Genentech, the US manufacturer, issued a media statement which is available here. More detailed background about the episode was contained in a statement from the UK Medicines and Healthcare products Regulatory Agency, which is available here.

Drug shortages: The problem of shortages of some drugs used in cancer treatments - including methotrexate which is used to treat primary central nervous system lymphomas (PCNSL) - is a continuing problem in the USA and worldwide. The American Society of Hematology and ASCO have both been applying pressure. Apparently, a significant cause in the case of methotrexate was the closure last year of Ben Venue Laboratories which is one of the four US makers. In Australia supplies of Doxil (known locally as Caelyx) used to treat breast and ovarian cancers, have just about disappeared due to the US manufacturer suspending its production.

 

Visas Tarptautinės sergančiųjų galvos smegenų augliais asociacijos 2012 m. vasario mėn. naujienas anglų kalba rasite čia.

 

Šaltinis: www.theibta.org

 
IBTA 2012 m. sausio mėn. naujienos (anglų k.) Spausdinti

Paediatric brain tumour research: In a recent report US Phrma identified 53 medicines in clinical trial development or FDA review for paediatric cancer of which 12 were specifically associated with brain tumours, while several others were being investigated for solid tumours in general.


The name, indication  and status of the brain tumour medicines or therapies are:  ARC-100 (medulloblastoma) Phase I/II; cintredekin besodotox  (glioma) Phase I; GliAtak (malignant brain tumors), Phase I; Nexavar (glioma), Phase II; nimotuzumab (recurrent glioma), Phase II; PTC299 (CNS cancer) Phase 1; SL-701 (glioma) Phase I/II; Tarceva (recurrent/refractory ependymoma) Phase II; TheraCIM (recurrent DIPG) Phase II; vismodegib (medulloblastoma) Phase II;  Xeloda (gliomas) Phase I; Xerecept (brain edema associated with brain tumors) Phase I/II.

 

Visas Tarptautinės sergančiųjų galvos smegenų augliais asociacijos 2012 m. sausio mėn. naujienas anglų kalba rasite čia.

 

Šaltinis: www.theibta.org

 
« PradžiaAnkstesnis11121314151617181920SekantisPabaiga »

Puslapis 11 iš 21